(Q43039208)

12 November 2017

title

Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

Dale J Kempf

1

1 reference

12 November 2017

Cheri Klein

2

1 reference

12 November 2017

Hui-Ju Chen

3

1 reference

12 November 2017

Larry L Klein

4

1 reference

12 November 2017

Clinton Yeung

5

1 reference

12 November 2017

John T Randolph

6

1 reference

12 November 2017

Yau Y Lau

7

1 reference

12 November 2017

Linda E Chovan

8

1 reference

12 November 2017

Zhiwen Guan

9

1 reference

12 November 2017

Lisa Hernandez

10

1 reference

12 November 2017

Teresa M Turner

11

1 reference

12 November 2017

Peter J Dandliker

12

1 reference

12 November 2017

Kennan C Marsh

13

1 reference

12 November 2017

publication date

1 January 2007

1 reference

Antiviral Chemistry & Chemotherapy

12 November 2017

published in

1 reference

12 November 2017

volume

18

1 reference

12 November 2017

issue

3

1 reference

12 November 2017

page(s)

163-167

1 reference

Mild hypothermia prevents brain edema and attenuates up-regulation of the astrocytic benzodiazepine receptor in experimental acute liver failure

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020701800306

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020701800306

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020701800306

Pharmacokinetic enhancement of protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020701800306

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020701800306

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020701800306

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020701800306

Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020701800306

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020701800306

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020701800306

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bio

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020701800306

10.1177/095632020701800306

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference